A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary.
Principal Investigator
Jubilee Brown, MD
Status
Terminated
Date Opened To Accrual
February 08 2010
Date Closed to Accrual
June 12 2020
Date of Study Termination
October 11 2024
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the activity of paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin (BEP) as a reference) for newly diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors.
Patient Population
Paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin (BEP) as a reference) for newly diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors.
Target Accrual
128
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.